Published on March 15, 2010 at 4:40 AM
Ipsen (Paris:IPN) announced today the initiation of dosing in two phase
II clinical studies to evaluate
efficacy and safety of BIM 23A760 in two
groups of patients, one suffering from carcinoid syndrome due to
neuroendocrine tumors, the other from
acromegaly.
“After the encouraging signs of efficacy observed in the first
clinical studies in healthy as well as acromegalic volunteers, we look
forward to further investigating BIM 23A760 efficacy and safety in
patients with neuroendocrine tumors or acromegaly. This very promising
compound is core to Ipsen’s strategy to enhance its fast-growing and
competitive endocrinology franchise, featuring among other drugs
Somatuline®, a somatostatin analogue developed
and marketed on a global scale” said Stéphane Thiroloix,
Executive Vice-President, Corporate Development, Ipsen.
Source Ipsen
3d5ce0b9-17a2-4c83-a6c4-45a7bdc83f50|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Acromegaly, Biotechnology, Carcinoid Syndrome, Diarrhea, Dopamine, Endocrinology, Growth Hormone, Hematology, Hormone, Insulin, Neurology, Oncology, Serotonin, Somatostatin